Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics,

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,899	137 Pages	IMARC Services Pvt. Ltd.	April, 2024	IMRC18712043

Best Price Guarantee
Price	from $3,899
Length	137 Pages
Publisher	IMARC Services Pvt. Ltd.
Published Date	April, 2024
SKU	IMRC18712043

Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Region 2024-2032

The global plasma fractionation market size reached US$ 25.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.

Plasma Fractionation Market Trends:
Protein products fractionated from human plasma are an essential class of therapeutics widely used to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune disorders. A significant rise in the prevalence of these conditions among a significant part of the population globally represents one of the key factors impelling the market growth. In addition, manufacturers are developing plasma fractionation with additional safety features due to the implementation of stringent regulations and standard controls and settings by governing agencies of numerous countries on quality assurance of biological products. Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global plasma fractionation market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, sector, application and end user.

Breakup by Product:

Immunoglobulins
Albumin
Coagulation factor VIII
Coagulation factor IX

Breakup by Sector:

Private Sector
Public Sector

Breakup by Application:

Neurology
Immunology
Hematology
Other Applications

Breakup by End User:

Hospitals and Clinics
Clinical Research Laboratories
Academic Institutes

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.

Key Questions Answered in This Report

1. What was the size of the global plasma fractionation market in 2023?
2. What is the expected growth rate of the global plasma fractionation market during 2024-2032?
3. What has been the impact of COVID-19 on the global plasma fractionation market?
4. What are the key factors driving the global plasma fractionation market?
5. What is the breakup of the global plasma fractionation market based on the product?
6. What is the breakup of the global plasma fractionation market based on the sector?
7. What is the breakup of the global plasma fractionation market based on the application?
8. What is the breakup of the global plasma fractionation market based on the end user?
9. What are the key regions in the global plasma fractionation market?
10. Who are the key players/companies in the global plasma fractionation market?

1 Preface
2 Scope and Methodology: 2.1 Objectives of the Study; 2.2 Stakeholders; 2.3 Data Sources; 2.3.1 Primary Sources; 2.3.2 Secondary Sources; 2.4 Market Estimation; 2.4.1 Bottom-Up Approach; 2.4.2 Top-Down Approach; 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction: 4.1 Overview; 4.2 Key Industry Trends
5 Global Plasma Fractionation Market: 5.1 Market Overview; 5.2 Market Performance; 5.3 Impact of COVID-19; 5.4 Market Forecast
6 Market Breakup by Product: 6.1 Immunoglobulins; 6.1.1 Market Trends; 6.1.2 Market Forecast; 6.2 Albumin; 6.2.1 Market Trends; 6.2.2 Market Forecast; 6.3 Coagulation factor VIII; 6.3.1 Market Trends; 6.3.2 Market Forecast; 6.4 Coagulation factor IX; 6.4.1 Market Trends; 6.4.2 Market Forecast
7 Market Breakup by Sector: 7.1 Private Sector; 7.1.1 Market Trends; 7.1.2 Market Forecast; 7.2 Public Sector; 7.2.1 Market Trends; 7.2.2 Market Forecast
8 Market Breakup by Application: 8.1 Neurology; 8.1.1 Market Trends; 8.1.2 Market Forecast; 8.2 Immunology; 8.2.1 Market Trends; 8.2.2 Market Forecast; 8.3 Hematology; 8.3.1 Market Trends; 8.3.2 Market Forecast; 8.4 Other Applications; 8.4.1 Market Trends; 8.4.2 Market Forecast
9 Market Breakup by End User: 9.1 Hospitals and Clinics; 9.1.1 Market Trends; 9.1.2 Market Forecast; 9.2 Clinical Research Laboratories; 9.2.1 Market Trends; 9.2.2 Market Forecast; 9.3 Academic Institutes; 9.3.1 Market Trends; 9.3.2 Market Forecast
10 Market Breakup by Region: 10.1 North America; 10.1.1 United States; 10.1.1.1 Market Trends; 10.1.1.2 Market Forecast; 10.1.2 Canada; 10.1.2.1 Market Trends; 10.1.2.2 Market Forecast; 10.2 Asia-Pacific; 10.2.1 China; 10.2.1.1 Market Trends; 10.2.1.2 Market Forecast; 10.2.2 Japan; 10.2.2.1 Market Trends; 10.2.2.2 Market Forecast; 10.2.3 India; 10.2.3.1 Market Trends; 10.2.3.2 Market Forecast; 10.2.4 South Korea; 10.2.4.1 Market Trends; 10.2.4.2 Market Forecast; 10.2.5 Australia; 10.2.5.1 Market Trends; 10.2.5.2 Market Forecast; 10.2.6 Indonesia; 10.2.6.1 Market Trends; 10.2.6.2 Market Forecast; 10.2.7 Others; 10.2.7.1 Market Trends; 10.2.7.2 Market Forecast; 10.3 Europe; 10.3.1 Germany; 10.3.1.1 Market Trends; 10.3.1.2 Market Forecast; 10.3.2 France; 10.3.2.1 Market Trends; 10.3.2.2 Market Forecast; 10.3.3 United Kingdom; 10.3.3.1 Market Trends; 10.3.3.2 Market Forecast; 10.3.4 Italy; 10.3.4.1 Market Trends; 10.3.4.2 Market Forecast; 10.3.5 Spain; 10.3.5.1 Market Trends; 10.3.5.2 Market Forecast; 10.3.6 Russia; 10.3.6.1 Market Trends; 10.3.6.2 Market Forecast; 10.3.7 Others; 10.3.7.1 Market Trends; 10.3.7.2 Market Forecast; 10.4 Latin America; 10.4.1 Brazil; 10.4.1.1 Market Trends; 10.4.1.2 Market Forecast; 10.4.2 Mexico; 10.4.2.1 Market Trends; 10.4.2.2 Market Forecast; 10.4.3 Others; 10.4.3.1 Market Trends; 10.4.3.2 Market Forecast; 10.5 Middle East and Africa; 10.5.1 Market Trends; 10.5.2 Market Breakup by Country; 10.5.3 Market Forecast
11 SWOT Analysis: 11.1 Overview; 11.2 Strengths; 11.3 Weaknesses; 11.4 Opportunities; 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis: 13.1 Overview; 13.2 Bargaining Power of Buyers; 13.3 Bargaining Power of Suppliers; 13.4 Degree of Competition; 13.5 Threat of New Entrants; 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape: 15.1 Market Structure; 15.2 Key Players; 15.3 Profiles of Key Players; 15.3.1 ADMA Biologics; 15.3.1.1 Company Overview; 15.3.1.2 Product Portfolio; 15.3.1.3 Financials; 15.3.2 Bio Products Laboratory Ltd.; 15.3.2.1 Company Overview; 15.3.2.2 Product Portfolio; 15.3.3 Boccard; 15.3.3.1 Company Overview; 15.3.3.2 Product Portfolio; 15.3.4 Grifols, S.A.; 15.3.4.1 Company Overview; 15.3.4.2 Product Portfolio; 15.3.4.3 Financials; 15.3.4.4 SWOT Analysis; 15.3.5 Hemarus Therapeutics Limited; 15.3.5.1 Company Overview; 15.3.5.2 Product Portfolio; 15.3.6 Intas Pharmaceuticals Limited; 15.3.6.1 Company Overview; 15.3.6.2 Product Portfolio; 15.3.7 LFB S.A.; 15.3.7.1 Company Overview; 15.3.7.2 Product Portfolio; 15.3.8 Merck Group; 15.3.8.1 Company Overview; 15.3.8.2 Product Portfolio; 15.3.8.3 Financials; 15.3.8.4 SWOT Analysis; 15.3.9 Octapharma AG; 15.3.9.1 Company Overview; 15.3.9.2 Product Portfolio; 15.3.9.3 SWOT Analysis; 15.3.10 PlasmaGen BioSciences Pvt. Ltd.; 15.3.10.1 Company Overview; 15.3.10.2 Product Portfolio; 15.3.11 SK Plasma Co. Ltd.; 15.3.11.1 Company Overview; 15.3.11.2 Product Portfolio; 15.3.12 Virchow Biotech Private Limited; 15.3.12.1 Company Overview; 15.3.12.2 Product Portfolio

Global Plasma Fractionation Market Size, Trends & Growth Opportunity, By Donor Type (Albumin, Immunoglobulins, Coagulation factor VIII, Coagulation factor IX), By Sector (Public Sector, Private sector), By Region and Forecast 2022- 2027.

December, 2022 | Published by: QualiKet Research | USD $3,950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028

September, 2023 | Published by: MarketsandMarkets | USD $4,950
Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

January, 2024 | Published by: 360iResearch | USD $4,749
Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

June, 2024 | Published by: 360iResearch | USD $4,949
China Plasma Protein Therapeutics Market (Product Type: Albumins, Immunoglobulins, Coagulation Factors, C1-esterase Inhibitors, and Others; and Therapeutic Area: Immunology, Neurology, Hematology, Pulmonology, and Others) - Industry Analysis, Size, Share,

January, 2023 | Published by: Transparency Market Research Pvt. Ltd. | USD $5,795
Plasma Fractionation Market Size, Trends, Analysis, and Outlook By Product (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), By Application (Neurology, Immunology, Hematology, Pulmonology, Others), By End-User (Hospitals and Clinics, Clinical Research Laboratories, Academic institutes), by Country, Segment, and Companies, 2024-2032

April, 2024 | Published by: VPA Research | USD $3,980

PDF E-mail From Publisher:	$3,899
Five User License Fulfilled by Publisher:	$4,899
Global Site License Fulfilled by Publisher:	$5,899

Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics,

Research Assistance

Other tasks

Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics,

Global Plasma Fractionation Market Size, Trends & Growth Opportunity, By Donor Type (Albumin, Immunoglobulins, Coagulation factor VIII, Coagulation factor IX), By Sector (Public Sector, Private sector), By Region and Forecast 2022- 2027.

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

China Plasma Protein Therapeutics Market (Product Type: Albumins, Immunoglobulins, Coagulation Factors, C1-esterase Inhibitors, and Others; and Therapeutic Area: Immunology, Neurology, Hematology, Pulmonology, and Others) - Industry Analysis, Size, Share,

Research Assistance

Other tasks